(Q34129154)

31 July 2017

title

Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface (English)

1 reference

31 July 2017

Sachi Horibata

4

1 reference

ORCID Public Data File 2021

author name string

Jennifer A A Gubbels

1

1 reference

31 July 2017

Brian Gadbaw

2

1 reference

31 July 2017

Ilia N Buhtoiarov

3

1 reference

31 July 2017

Arvinder K Kapur

5

1 reference

31 July 2017

Dhara Patel

6

1 reference

31 July 2017

Jacquelyn A Hank

7

1 reference

31 July 2017

Stephen D Gillies

8

1 reference

31 July 2017

Paul M Sondel

9

1 reference

31 July 2017

Manish S Patankar

10

1 reference

31 July 2017

Joseph Connor

11

1 reference

31 July 2017

publication date

27 July 2011

1 reference

Cancer Immunology, Immunotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

60

1 reference

31 July 2017

issue

12

1 reference

31 July 2017

page(s)

1789-1800

1 reference

Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

LFA-1 and CD2 synergize for the Erk1/2 activation in the Natural Killer (NK) cell immunological synapse

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Intratumoral immunocytokine treatment results in enhanced antitumor effects

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Up on the tightrope: natural killer cell activation and inhibition

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

WIP is essential for lytic granule polarization and NK cell cytotoxicity

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Formation of a WIP-, WASp-, actin-, and myosin IIA-containing multiprotein complex in activated NK cells and its alteration by KIR inhibitory signaling

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

The human natural killer cell immune synapse

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Redirecting effector T cells through their IL-2 receptors.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Immunocytokines: a new approach to immunotherapy of melanoma.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Clinical effects and toxicity of interleukin-2 in patients with cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Intracytoplasmic phosphorylation sites of Tac antigen (p55) are not essential for the conformation, function, and regulation of the human interleukin 2 receptor

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

The human interleukin-2 receptor

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Therapeutic uses of interleukin-2 and lymphokine-activated killer (LAK) cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

The impact of T-cell immunity on ovarian cancer outcomes

28 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1072-9

Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL 2)-containing preparations. Preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1072-9

Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1072-9

The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1072-9

A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1072-9

Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1072-9

T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1072-9

NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1072-9

NK cells and cancer immunosurveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1072-9

Influencing Receptor−Ligand Binding Mechanisms with Multivalent Ligand Architecture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1072-9

The mature activating natural killer cell immunologic synapse is formed in distinct stages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1072-9

A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Biology of the interleukin-2 receptor

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153733

Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2

28 October 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1072-9

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

21 January 2018

1 reference

12 December 2020

Tumour inhibitory effects of TCGF/IL-2/-containing preparations

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Human interleukin 2 receptor (Tac antigen)

1 reference

12 December 2020

Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes

1 reference

12 December 2020

Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2

1 reference

12 December 2020

Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy

1 reference

12 December 2020

Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma

1 reference

12 December 2020

Immunocytokines: a promising approach to cancer immunotherapy

1 reference

12 December 2020

Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors

1 reference

12 December 2020

The structure of interleukin-2 complexed with its alpha receptor

1 reference

12 December 2020

Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125)

1 reference

12 December 2020

10.1007/S00262-011-1072-9

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference

31 July 2017

1 reference